[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:pancreatic-adenocarcinoma:gtpase-kras":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Pancreatic Adenocarcinoma","GTPase KRas",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07671339","A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:15:51.395565Z","2026-07-05T03:45:20.372123Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07621718","Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )",[20],"Phase 3","2026-08-26T02:17:38.215063Z","2026-06-04T01:30:07.905536Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07594067","TCR1188-ABC Cells in KRAS-mutated Cancers",[12],"2026-08-26T02:16:38.053590Z","2026-07-19T19:36:05.077181Z"]